1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Company
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:

- sales of medicines (80.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;

- royalties (15.1%) ;

- other (4.4%): primarily revenues from partnership agreements.

Number of employees : 9 610 people.
Sales per Business
20202021Delta
Product10 692.2079.5%8 846.9080.6% -17.26%
Anti-CD20 Therapeutic Programs1 977.8014.7%1 658.5015.1% -16.14%
Other774.605.8%476.304.3% -38.51%
USD in Million
Sales per region
20202021Delta
United States8 531.1063.5%5 832.3053.1% -31.63%
Europe3 664.6027.3%2 635.7024% -28.08%
Germany--1 162.4010.6%-
Asia629.604.7%724.706.6% +15.1%
Other619.304.6%626.605.7% +1.18%
USD in Million
Managers
Name Title Age Since
Michel Vounatsos Chief Executive Officer & Director 59 2017
Michael McDonnell Chief Financial Officer & Executive Vice President 57 2020
Alphonse Galdes EVP-Pharmaceutical Operations & Technology 68 2019
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP - 2020
Priya Singhal Head-Research & Development 53 2021
Michael Hencke Manager-Investor Relations - 2014
Michael Dambach Treasurer & Vice President - -
Susan H. Alexander Secretary, Chief Legal Officer & Executive VP 64 2014
Anabella Villalobos, Dr. SVP-Biotherapeutic & Medicinal Sciences - 2017
Daniel Karp Executive Vice President-Corporate Development 43 2018
Members of the board
Name Title Age Since
Stelios Papadopoulos Director 72 2008
Alexander Denner Independent Director 51 2009
Richard Charles Mulligan, Dr. Independent Director 66 2009
Caroline D. Dorsa Independent Director 61 2010
Eric K. Rowinsky, Dr. Independent Director 64 2011
Stephen A. Sherwin, Dr. Independent Director 72 2010
William A. Hawkins Independent Director 67 2019
Jesus B. Mantas Independent Director 52 2019
Maria C. Freire, Dr. Independent Director 66 2021
William D. Jones Independent Director 65 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 169,000,000 143,748,000 85.1% 23,800,000 14.1% 85.1%
Shareholders
NameEquities%
PRIMECAP Management Co. 15,757,405 10.8%
The Vanguard Group, Inc. 11,537,299 7.88%
Capital Research & Management Co. 10,955,000 7.48%
SSgA Funds Management, Inc. 7,208,906 4.92%
Wellington Management Co. LLP 6,249,526 4.27%
Capital Research & Management Co. (Global Investors) 5,456,600 3.73%
BlackRock Fund Advisors 3,244,410 2.22%
Icahn Associates Holding LLC 3,215,051 2.20%
Perry Corp. (New York) 2,998,629 2.05%
Geode Capital Management LLC 2,806,664 1.92%
Holdings
NameEquities%Valuation
SAGE THERAPEUTICS, INC. (SAGE) 6,241,473 10.6% 201,599,578 USD
SANGAMO THERAPEUTICS, INC. (SGMO) 24,152,466 16.5% 99,991,209 USD
Markets and indexes
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 500
Stock Exchange Codes
- Bloomberg Code :  BIIB:US
- Reuters Code :  BIIB.O
- Datastream Code :  
Company contact information
Biogen Inc.
225 Street Binney
MA 02142 Cambridge, Massachusetts

Phone : +1 617 679-2000
Fax :
web site : https://www.biogen.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Biogen Inc.